Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v5-EN | Version v3-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2025-05-02 | 2025-02-28 |
| Drug Identification Number | 00786306 | 00786306 |
| Brand name | POTASS CHLOR 40MEQ 5% DEX AND 0.9% SOD CHLOR | POTASS CHLOR 40MEQ 5% DEX AND 0.9% SOD CHLOR |
| Common or Proper name | 40 mmol/L Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection, USP, 1000 mL VIAFLEX PVC Container (specific codes only) | 40 mmol/L Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection, USP, 1000 mL VIAFLEX PVC Container (specific codes only) |
| Company Name | BAXTER CORPORATION | BAXTER CORPORATION |
| Ingredients | POTASSIUM CHLORIDE SODIUM CHLORIDE DEXTROSE | POTASSIUM CHLORIDE SODIUM CHLORIDE DEXTROSE |
| Strength(s) | 300MG 900MG 5G | 300MG 900MG 5G |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 12 ea/ca | 12 ea/ca |
| ATC code | B05BB | B05BB |
| ATC description | I.V. SOLUTIONS | I.V. SOLUTIONS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-01-07 | 2025-01-07 |
| Actual start date | 2025-01-07 | 2025-01-07 |
| Estimated end date | 2025-05-05 | 2025-04-30 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Suggested substitute: JB1064 – 5% DEX & 0.9% NACL INJ USP 1L, with addition of KCl. | Suggested substitute: JB1064 – 5% DEX & 0.9% NACL INJ USP 1L, with addition of KCl. |
| Health Canada comments |